Biotech News
Related news
NTLAIntellia2026-06-01 11:30 EST
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
NTLAIntellia2026-04-27 11:00 EST
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
ABEOAbeona Therapeutics2026-08-03 11:30 EST
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPTSarepta Therapeutics2026-07-29 21:00 EST
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MXCTMaxCyte2026-03-31 20:05 EST
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TSHATaysha Gene Therapies2026-08-07 12:00 EST
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MGTXMeiraGTx2026-08-06 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ABEOAbeona Therapeutics2026-08-06 11:30 EST
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
CRSPCRISPR Therapeutics2026-08-03 20:15 EST
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
SRPTSarepta Therapeutics2026-07-27 12:30 EST
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
Intellia
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...
Recent company news
NTLAIntellia2026-08-07 20:01 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-08-06 11:00 EST
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
NTLAIntellia2026-07-30 12:00 EST
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
NTLAIntellia2026-07-06 20:05 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-06-13 11:30 EST
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Stock data
- Close
- 11.24 USD
- Market cap
- 1.83B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States